CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases
Systemic sclerosis (SSc) data presented at ACR Convergence 2026 showed 83% (5/6) of patients receiving standard lymphodepletion achieved a clinical response (rCRISS-25) at Month 3, with all responders maintaining response
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


